期刊论文

Huang, W.;Qu, X.;Xu, W.;Wang, Y.

英文

Cell

0092-8674

2021

184

9

2362-2371.e9

10.1016/j.cell.2021.02.042

We gratefully acknowledge the authors from the originating laboratories and the submitting laboratories where genetic sequence data were generated and shared via GISAID, enabling this research. This work was supported by the General Program of National Natural Science Foundation of China (82073621), the Bill and Melinda Gates Foundation (INV-006379), the National Science and Technology Major Projects of Drug Discovery (2018ZX09101001), and the National Science and Technology Major Projects of Infectious Disease (2017ZX10304402). Y.W. and W.H. conceived, designed, and supervised the experiments. J.N. Li Zhang, Q. Li, W.H. and Y.W. wrote the manuscript. Q. Li, J.W. R.D. H.W. Y.Z. T.L. S.L. M.Z. C.Z. H. Liu, H.Q. L.N. J.L. M.W. X.L. and H. Liang performed the experiments. L.X. Linqui Zhang, Y. Shen, and Y. Shi provided some monoclonal antibodies and aided in data analysis. W.X. and X.Q. provided the convalescent sera and clinical information. All the authors have read and approved the final manuscript. The authors declare no competing interests.

本校为其他机构

The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in spike are now dominant in South Africa and are rapidly spreading to other countries. Here, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in infectivity was observed. Notably, the susceptibility of the 501Y.V2 variants to 12 of 17 neutralizing monoclonal antibodies was substantially diminished, and the neutralization abil...